Correction: An observational study of the effectiveness and safety of nivolumab plus chemotherapy for untreated advanced or recurrent gastric cancer in Japanese real-world settings: the G-KNIGHT study - Summary - MDSpire

Correction: An observational study of the effectiveness and safety of nivolumab plus chemotherapy for untreated advanced or recurrent gastric cancer in Japanese real-world settings: the G-KNIGHT study

  • By

  • Shigenori Kadowaki

  • Tomoyuki Otsuka

  • Keiko Minashi

  • Shinichi Nishina

  • Hiroshi Yabusaki

  • Chiaki Inagaki

  • Tomohiro Nishina

  • Hisateru Yasui

  • Hiroshi Matsuoka

  • Nozomu Machida

  • Masahiro Tsuda

  • Fumio Nagashima

  • Hisashi Hosaka

  • Junichi Matsubara

  • Hiroyuki Arai

  • Satoshi Ida

  • Yuya Kimijima

  • Yuko Matsuda

  • Manabu Muto

  • Kei Muro

  • June 18, 2026

  • 0 min

Share

Objective:

To correct previously published data regarding the efficacy of nivolumab combined with chemotherapy in treating advanced or recurrent gastric cancer.

Approach:
    Key Findings:
    • The corrected ORR is 65.6% (95% CI, 59.9–70.9%).
    • The corrected DCR is 91.6% (95% CI, 87.9–94.5%).
    • Among the patients, 8 (2.7%) achieved a complete response, 188 (62.9%) achieved a partial response, and 78 (26.1%) achieved stable disease.
    Interpretation:

    The correction clarifies the efficacy outcomes of the treatment in the study population.

    Limitations:
    • No additional limitations regarding the study or corrections were provided.
    Conclusion:

    The corrections ensure accurate reporting of the study's findings on the efficacy of nivolumab combined with chemotherapy.

    Sources:

Original Source(s)

Correction: An observational study of the effectiveness and safety of nivolumab plus chemotherapy for untreated advanced or recurrent gastric cancer in Japanese real-world settings: the G-KNIGHT study

  • by Shigenori Kadowaki, Tomoyuki Otsuka, Keiko Minashi, Shinichi Nishina, Hiroshi Yabusaki, Chiaki Inagaki, Tomohiro Nishina, Hisateru Yasui, Hiroshi Matsuoka, Nozomu Machida, Masahiro Tsuda, Fumio Nagashima, Hisashi Hosaka, Junichi Matsubara, Hiroyuki Arai, Satoshi Ida, Yuya Kimijima, Yuko Matsuda, Manabu Muto, Kei Muro

  • June 18, 2026

Related Content

Correction: Stereotactic radiotherapy for brain metastases: indications, dose fractionation, technological innovations, and evolving combination strategies – a comprehensive review

Research advances and application prospects of CAR-T therapy in the treatment of age-related diseases

Editorial: Innovative strategies in overcoming glioblastoma: advancements in treatment and research